Posted by Michael Wonder on 06 Jul 2020
CMS’s proposed Medicaid best price loophole for value based purchasing of drugs
6 July 2020 - For three decades, US pharmaceutical companies have agreed to sell their products to Medicaid programs at the lowest price available in the market.
In return, Medicaid programs cover and pay for every FDA approved product the companies sell, even when the lowest price is still excessive.
Pharmaceutical companies want out of the first part of this longstanding deal, and the administration has capitulated in proposing a gaping loophole in the Medicaid best price rules.
